Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled, Double-Masked, Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Trial Profile

A Randomized Controlled, Double-Masked, Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risuteganib (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Allegro Ophthalmics
  • Most Recent Events

    • 08 Oct 2019 According to an Allegro Ophthalmics media release, data from the study will be presented at the American Academy of Ophthalmology's 123rd annual meeting (AAO 2019).
    • 03 Sep 2019 According to an Allegro Ophthalmics media release, data from the study will be presented during the 19th European Society of Retina Specialists (EURETINA) Congress 2019 and The Retina Society 2019 Annual Meeting.
    • 08 Jul 2019 Planned End Date changed from 28 Jun 2019 to 28 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top